Opus Genetics, Inc. Net Fee Amt
Opus Genetics, Inc. (IRD) had Net Fee Amt of $32.14 thousand as of 2026-08-07, per its S-3 filed 2026-08-07.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-07
- 2026-08-07: Net Fee Amt $32.14K.
- 2026-06-05: Net Fee Amt $1.58K.
- 2026-05-11: Net Fee Amt $670.41.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-07 | $32.14K S-3 · filed 2026-08-07 |
| 2026-06-05 | $1.58K S-3 · filed 2026-06-05 |
| 2026-05-11 | $670.41 S-8 · filed 2026-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |